-
1Academic Journal
Συγγραφείς: Maria A. Leonova, Nikolay N. Murashkin, М. А. Леонова, Н. Н. Мурашкин
Πηγή: Pediatric pharmacology; Том 19, № 6 (2022); 479-483 ; Педиатрическая фармакология; Том 19, № 6 (2022); 479-483 ; 2500-3089 ; 1727-5776
Θεματικοί όροι: клинический случай, dystrophic epidermolisys bullosa, epidermolysis bullosa, clinical case, дистрофический буллезный эпидермолиз, врожденный буллезный эпидермолиз, буллезный эпидермолиз
Περιγραφή αρχείου: application/pdf
Relation: https://www.pedpharma.ru/jour/article/view/2230/1449; Kim WB, Alavi A, Walsh S, et al. Epidermolysis bullosa pruriginosa: a systematic review exploring genotype-phenotype correlation. Am J Clin Dermatol. 2015;16(2):81–87. https://doi.org/10.1007/s40257-015-0119-7; Ghosh S, Chaudhuri S, Jain VK. Epidermolysis bullosa pruriginosa: a rare presentation with asymptomatic lesions. Indian J Dermatol Venereol Leprol. 2013;79(2):235–237. https://doi.org/110.4103/0378-6323.107645; Kim WB, Alavi A, Pope E, et al. Epidermolysis Bullosa Pruriginosa: Case Series and Review of the Literature. Int J Low Extrem Wounds. 2015;14(2):196–199. https://doi.org/10.1177/1534734615572469; Nakamura E, Majima Y, Hashizume H, et al. Dominant dystrophic epidermolysis bullosa pruriginosa with a COL7A1 exon 87 c.6898C>T mutation. Clin Exp Dermatol. 2019;44(1):82–84. https://doi.org/10.1111/ced.13715; Loh CC, Kim J, Su JC, et al. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). J Am Acad Dermatol. 2014;70(1):89–97.e1-e13. https://doi.org/10.1016/j.jaad.2013.09.041; Jain SV, Harris AG, Su JC, et al. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2017;31(4):692–698. https://doi.org/10.1111/jdv.13953; de Onis M, Onyango AW, Borghi E, et al. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007;85(9):660–667. https://doi.org/10.2471/blt.07.043497; Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103–1126. https://doi.org/10.1016/j.jaad.2014.01.903; Vivehanantha S, Carr RA, McGrath JA, et al. Epidermolysis bullosa pruriginosa: a case with prominent histopathologic inflammation. JAMA Dermatol. 2013;149(6):727–731. https://doi.org/10.1001/jamadermatol.2013.155; Banky JP, Sheridan AT, Storer EL, et al. Successful treatment of epidermolysis bullosa pruriginosa with topical tacrolimus. Arch Dermatol. 2004;140(7):794–796. https://doi.org/10.1001/archderm.140.7.794; Ferreira S, Azevedo A, Velho GC, et al. Epidermolysis Bullosa Pruriginosa successfully treated with concomitant topical and systemic agents. Australas J Dermatol. 2020;61(4):355–357. https://doi.org/10.1111/ajd.13342; Ertop P, Vural S, Gökpınar Ili E, et al. Promising effect of intravenous immunoglobulin therapy for epidermolysis bullosa pruriginosa. Int J Dermatol. 2020;59(7):851–855. https://doi.org/10.1111/ijd.14951; Zhou AG, Little AJ, Antaya RJ. Epidermolysis bullosa pruriginosa treated with dupilumab. Pediatr Dermatol. 2021;38(2):526–527. https://doi.org/10.1111/pde.14493; Shehadeh W, Sarig O, Bar J, et al. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br J Dermatol. 2020;182(6):1495–1497. https://doi.org/10.1111/bjd.18855; Clawson RC, Duran SF, Pariser RJ. Epidermolysis bullosa pruriginosa responding to dupilumab. JAAD Case Rep. 2021;16:69–71. https://doi.org/10.1016/j.jdcr.2021.07.036; Jiang X, Wang H, Lee M, et al. Epidermolysis Bullosa Pruriginosa Treated With Baricitinib. JAMA Dermatol. 2021;157(10):1243–1244. https://doi.org/10.1001/jamadermatol.2021.3174; Chen KJ, Fang S, Ye Q, et al. Successful use of tofacitinib in epidermolysis bullosa pruriginosa. Clin Exp Dermatol. 2022;47(3):598–600. https://doi.org/10.1111/ced.14998; Kaushik A, Mahajan R, Karim A, et al. Successful use of cyclosporine in epidermolysis bullosa pruriginosa. Dermatol Ther. 2020;33(6):e14489. https://doi.org/10.1111/dth.14489; Takahashi T, Mizutani Y, Ito M, et al. Dystrophic epidermolysis bullosa pruriginosa successfully treated with immunosuppressants. J Dermatol. 2016;43(11):1391–1392. https://doi.org/10.1111/1346-8138.13406; Ranugha PS, Mohanan S, Chandrashekar L, et al. Epidermolysis bullosa pruriginosa showing good response to low-dose thalidomide — a report of two cases. Dermatol Ther. 2014;27(1):60–63. https://doi.org/10.1111/dth.12047; Pallesen KAU, Lindahl KH, Bygum A. Dominant Dystrophic Epidermolysis Bullosa Pruriginosa Responding to Naltrexone Treatment. Acta Derm Venereol. 2019;99(12):1195–1196. https://doi.org/10.2340/00015555-3304; Caroppo F, Milan E, Giulioni E, Belloni Fortina A. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab. J Eur Acad Dermatol Venereol. 2022;36(5):e365-e367. https://doi.org/10.1111/jdv.17887; https://www.pedpharma.ru/jour/article/view/2230
-
2Academic Journal
Συγγραφείς: V. I. Albanova, M. A. Nefedova, E. S. Monchakovskaya, V. V. Chikin, V. A. Smolyannikova, A. E. Karamova
Πηγή: Vestnik Dermatologii i Venerologii, Vol 0, Iss 3, Pp 83-89 (2017)
Θεματικοί όροι: врожденный буллезный эпидермолиз, 03 medical and health sciences, рецессивный дистрофический буллезный эпидермолиз, 0302 clinical medicine, RL1-803, hereditary epidermolysis bullosa, squamous-cell carcinoma, recessive dystrophic epidermolysis bullosa, Dermatology, плоскоклеточный рак кожи, 3. Good health
-
3Academic Journal
Συγγραφείς: A. E. Karamova, V. V. Chikin, V. I. Albanova, V. A. Smolyannikova, M. A. Nefedova, E. S. Monchakovskaya
Πηγή: Vestnik Dermatologii i Venerologii, Vol 0, Iss 3, Pp 83-89 (2017)
Θεματικοί όροι: врожденный буллезный эпидермолиз, рецессивный дистрофический буллезный эпидермолиз, плоскоклеточный рак кожи, hereditary epidermolysis bullosa, recessive dystrophic epidermolysis bullosa, squamous-cell carcinoma, Dermatology, RL1-803
Περιγραφή αρχείου: electronic resource
Relation: https://www.vestnikdv.ru/jour/article/view/243; https://doaj.org/toc/0042-4609; https://doaj.org/toc/2313-6294
Σύνδεσμος πρόσβασης: https://doaj.org/article/fd2ef1efb0dd47a7a9d5ce891f244e6c
-
4Academic Journal
Συγγραφείς: Kubanov A.A., Karamova A.E., Albanova V.I., Monchakovskaya E.S.
Πηγή: Vestnik dermatologii i venerologii; Vol 95, No 1 (2019); 30-40 ; Вестник дерматологии и венерологии; Vol 95, No 1 (2019); 30-40 ; 2313-6294 ; 0042-4609 ; 10.25208/0042-4609-2019-95-1
Θεματικοί όροι: congenital epidermolysis bullosa, border epidermolysis bullosa, recessive dystrophic epidermolysis bullosa, erosions, healing, external therapy, atraumatic non-adherent wound dressings, врожденный буллезный эпидермолиз, пограничный буллезный эпидермолиз, рецессивный дистрофический буллезный эпидермолиз, эрозии, заживление, наружная терапия, атравматичные неадгезивные перевязочные средства
Περιγραφή αρχείου: application/pdf
Relation: https://vestnikdv.ru/jour/article/view/464/434; https://vestnikdv.ru/jour/article/view/464